In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Roivant Sciences Ltd (NASDAQ: ROIV) closed at $20.22 in the last session, down -2.84% from day before closing price of $20.81. In other words, the price has decreased by -$2.84 from its previous closing price. On the day, 7.98 million shares were traded. ROIV stock price reached its highest trading level at $20.81 during the session, while it also had its lowest trading level at $20.115.
Ratios:
We take a closer look at ROIV’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 33.70 and its Current Ratio is at 33.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on September 02, 2025, initiated with a Buy rating and assigned the stock a target price of $16. On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $17.Wolfe Research initiated its Outperform rating on February 15, 2024, with a $17 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 19 ’25 when MANCHESTER KEITH S sold 1,300,000 shares for $20.23 per share. The transaction valued at 26,304,500 led to the insider holds 18,047,727 shares of the business.
Gold Daniel Allen sold 1,300,000 shares of ROIV for $26,304,500 on Nov 19 ’25. The Director now owns 18,047,727 shares after completing the transaction at $20.23 per share. On Nov 19 ’25, another insider, QVT Financial LP, who serves as the Director by Deputization of the company, sold 1,300,000 shares for $20.23 each. As a result, the insider received 26,304,500 and left with 18,047,727 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 14062839808 and an Enterprise Value of 10218978304. For the stock, the TTM Price-to-Sale (P/S) ratio is 691.73 while its Price-to-Book (P/B) ratio in mrq is 3.20. Its current Enterprise Value per Revenue stands at 502.68 whereas that against EBITDA is -9.22.
Stock Price History:
The Beta on a monthly basis for ROIV is 1.23, which has changed by 0.71699667 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, ROIV has reached a high of $21.35, while it has fallen to a 52-week low of $8.73. The 50-Day Moving Average of the stock is 10.77%, while the 200-Day Moving Average is calculated to be 55.50%.
Shares Statistics:
According to the various share statistics, ROIV traded on average about 8.48M shares per day over the past 3-months and 6052740 shares per day over the past 10 days. A total of 689.70M shares are outstanding, with a floating share count of 432.70M. Insiders hold about 37.79% of the company’s shares, while institutions hold 63.75% stake in the company. Shares short for ROIV as of 1763078400 were 23049893 with a Short Ratio of 2.72, compared to 1760486400 on 25271869. Therefore, it implies a Short% of Shares Outstanding of 23049893 and a Short% of Float of 4.42.
Earnings Estimates
The dynamic stock of Roivant Sciences Ltd (ROIV) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.25 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$0.86 and -$1.46 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.19, with 4.0 analysts recommending between -$0.74 and -$1.9.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $6.14M. It ranges from a high estimate of $15M to a low estimate of $1.78M. As of. The current estimate, Roivant Sciences Ltd’s year-ago sales were $9.02MFor the next quarter, 8 analysts are estimating revenue of $6.75M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $2M.
A total of 10 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $33.7M, while the lowest revenue estimate was $3.74M, resulting in an average revenue estimate of $15.9M. In the same quarter a year ago, actual revenue was $29.05MBased on 10 analysts’ estimates, the company’s revenue will be $118.02M in the next fiscal year. The high estimate is $466.13M and the low estimate is $6.28M.
